Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo Eyes $115 Billion In Rx-To-OTC Switches On The Horizon

This article was originally published in The Pink Sheet Daily

Executive Summary

The private labeler sees about $115 billion worth of branded Rx products with potential to switch OTC, including statins and longer-shot switches for diabetes, hypertension and topical steroid drugs. Perrigo’s shorter-term pipeline includes equivalents of proton pump inhibitors Nexium, Protonix and Aciphex.


Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts